Exhibit 10.17

THIS SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF UNITS (THE "UNIT
OFFERING"), EACH UNIT COMPRISED OF ONE (1) SHARE OF COMMON STOCK (THE "SHARES")
AND ONE (1) CLASS B COMMNON STOCK PURCHASE WARRANT (THE "CLASS B WARRANT"). THE
UNIT OFFERING IS BEING IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S.
PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S PROMULGATED BY THE UNITED
STATES SECURITIES AND EXCHANGE COMMISSION (THE "SEC") UNDER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE "ACT").

THE SHARES AND CLASS B WARRANT THAT ARE SUBJECT TO THIS UNIT SUBSCRIPTION
AGREEMENT (THE "SUBSCRIPTION AGREEMENT") HAVE NOT BEEN REGISTERED UNDER THE ACT,
OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE
OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS
(AS DEFINED HEREIN) EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S
UNDER THE ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING
THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE ACT.

OWC PHARMACEUTICAL RESARCH CORP.
(A Delaware corporation)

UNIT SUBSCRIPTION AGREEMENT

DATED: November 3, 2016

1. Unit Offering

1.1 On the basis of the representations and warranties and subject to the terms
and conditions set forth in this Unit Subscription Agreement (the "Subscription
Agreement"), Michepro Holding Ltd, by Mr. Uri Heler as trustee (the "Investor")
hereby agrees to subscribe for and purchase 2,307,692 Units (the "Unit
Offering") offered by OWC Pharmaceutical Research Corp., a Delaware corporation
with offices located at 14 Shacham Street, P.O.B. 8324, Petach Tikva 4918103
Israel (the “Company”), at a Unit purchase price of US$0.13 per Unit (the Unit
Purchase Price") pursuant to the terms and conditions set forth in this
Subscription Agreement.
1.2 The undersigned Investor understands that: (i) this Unit Offering by the
Company is being made only to persons/institutions who are not U.S. Persons, as
defined in Rule 902 of Regulation S promulgated by the United States Securities
and Exchange Commission (“SEC”) under the Securities Act of 1933, as amended
(the “Act”) and that the Company will not offer Units nor accept subscriptions
from any person and/or entity that is not a U.S. Person as defined in Rule 902
of Regulation S; and (ii) each Unit is comprised of one (1) share of the
Company's common stock (the "Shares") and one (1) 761,538 Class G Warrant
exercisable for a period of twenty four (24) months to purchase additional
Shares at an exercise price of $0.25 per Share (the "Warrant Exercise Price"),
and 761,538 Class H Warrant exercisable for a period of thirty six (36 ) months
to purchase additional Shares at an exercise price of $0.4 per Share (the
"Warrant Exercise Price").
1.3 On the basis of the representations and warranties of the Investor and
subject to the terms and conditions set forth herein, the Company, by its
execution and delivery of the counter-signed copy of this Subscription
Agreement, hereby irrevocably agrees to accept the subscription and sell to the
undersigned the Units subscribed for herein.
1.4 Subject to the terms hereof, this Subscription Agreement will be effective
upon receipt by the Company of the proceeds equal to the Unite Purchase Price
multiplied by the number of Units subject to this Subscription Agreement (the
"Subscription Proceeds").

2. Payment of Unit Purchase Price
The Investor understands that the Subscription Proceeds are payable to the
Company by electronic wire transfer of 300, 000 $ pursuant to wiring
instructions set forth below.

3. Documents/Deliveries Required from the Investor
3.1 The Investor understands and agrees that as a condition to the Company's
acceptance of this subscription, the undersigned will complete, sign and return
to the Company an executed copy of this Subscription Agreement together with any
and all attachments hereto.
3.2 The Investor will complete, sign and return to the Company as soon as
possible, on request by the Company, any other documents, questionnaires,
notices and undertakings as may be required by regulatory authorities and
applicable law.
3.3 The Investor will pay/deliver the Subscription Proceeds to the Company as
provided in Section 2 above.

4. Acknowledgements of Investor
4.1 The Investor acknowledges and agrees that:
(i) neither the Shares being offered as part of the Units nor any Shares
issuable upon exercise of the Class G & Class H have been registered under the
Act, or under any state securities or "blue sky" laws of any state of the United
States, and, unless so registered, neither the Shares nor any Shares underlying
the Class G & Class H may be offered or sold in the United States or, directly
or indirectly, to U.S. Persons, as that term is defined in Rule 902 of
Regulation S under the Act, except in accordance with the provisions of
Regulation S, pursuant to an effective registration statement under the Act, or
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Act;
(ii) the Investor acknowledges that the Company has not undertaken, and will
have no obligation, to register the Shares or any underlying Shares under the
Act;
the decision to execute this Subscription Agreement and fund the Loan pursuant
to the Note Offering has not been based upon any oral or written representation
as to fact or otherwise made by or on behalf of the Company, and such decision
is based entirely upon a review of information (the receipt of which is hereby
acknowledged) which has been filed by the Company with the SEC and/or in
compliance, or intended compliance, with applicable securities legislation and
regulations, including information filed with the OTC Pink operated by OTC
Markets Group Inc. (collectively, the "Public Record");if the Company has
presented a business plan to the Investor, the Investor acknowledges that the
business plan may not be achieved or be achievable;
(v) no securities commission or similar regulatory authority has reviewed or
passed on the merits of the Units; there is no government or other insurance
covering the Units; there are risks associated with an investment in the Units,
as more fully described in certain information forming part of the Public
Record; the Investor and the Investor’s advisor(s), if any, have had a
reasonable opportunity to ask questions of and receive answers from the Company
in connection with the Unit Offering and to obtain additional information, to
the extent possessed or obtainable without unreasonable effort or expense,
necessary to verify the accuracy of the information about the Company; the books
and records of the Company were available upon reasonable notice for inspection,
subject to certain confidentiality restrictions, by the Investor during
reasonable business hours at its principal place of business, and all documents,
records and books in connection with the distribution of the Units hereunder
have been made available for inspection by the Investor, the Investor’s attorney
and/or advisor(s), if any; the Investor will indemnify and hold harmless the
Company and, where applicable, its directors, officers, employees, agents,
advisors and shareholders, from and against any and all loss, liability, claim,
damage and expense whatsoever (including, but not limited to, any and all fees,
costs and expenses whatsoever reasonably incurred in investigating, preparing or
defending against any claim, lawsuit, administrative proceeding or investigation
whether commenced or threatened) arising out of or based upon any representation
or warranty of the Investor contained herein or in any document furnished by the
Investor to the Company in connection herewith being untrue in any material
respect or any breach or failure by the Investor to comply with any covenant or
agreement made by the Investor to the Company in connection therewith;
(xi) neither the Shares nor the Shares underlying the Class G & Class H are or
will be listed on any stock exchange or automated dealer quotation system and no
representation has been made to the Investor that any of the Units or underlying
Shares will become listed on any stock exchange or automated dealer quotation
system; the Units and underlying Shares are assignable only with the prior
written consent of the Company, which consent will not be unreasonably denied,
provided that any such transfer is made in accordance with the provisions of
Regulation S, pursuant to an effective registration statement under the Act or
pursuant to an available exemption from the registration requirements of the
Act; the statutory and regulatory basis for the exemption claimed for the Units
and Shares, although in technical compliance with Regulation S, would not be
available if the offering is part of a plan or scheme to evade the registration
provisions of the Act; the Investor has been advised to consult the Investor’s
own legal, tax and other advisors with respect to the merits and risks of an
investment in the Units and with respect to applicable resale restrictions, and
it is solely responsible (and the Company is not in any way responsible) for
compliance with any applicable laws of the jurisdiction in which the Investor is
resident in connection with the distribution of the Units or underlying
securities hereunder; and
(b) applicable resale restrictions. this Subscription Agreement is not
enforceable by the Investor unless it has been accepted by the Company upon
receipt of the Subscription Proceeds for the Units.

5. Representations, Warranties and Covenants of the Investor5.1 The Investor
hereby represents and warrants to and covenants with the Company (which
representations, warranties and covenants will survive the execution and
delivery of this Subscription Agreement) that:
(i) the Investor has the legal capacity and competence to enter into and execute
this Subscription Agreement and to take all actions required pursuant hereto
and, if the Investor is a corporation, it is duly incorporated and validly
subsisting under the laws of its jurisdiction of incorporation and all necessary
approvals by its directors, shareholders and others have been obtained to
authorize execution and performance of this Subscription Agreement on behalf of
the Investor; entering into of this Subscription Agreement and the transactions
contemplated hereby do not result in the violation of any of the terms and
provisions of any law applicable to, or the corporate documents of, the Investor
or of any agreement, written or oral, to which the Investor may be a party or by
which the Investor is or may be bound; the Investor has duly executed and
delivered this Subscription Agreement and it constitutes a valid and binding
agreement of the Investor enforceable against the Investor; the Investor is not
a U.S. Person; the Investor is not acquiring the Units for the account or
benefit of, directly or indirectly, any U.S. Person; the Investor is resident of
the jurisdiction set out under the heading "Name and Address of Investor" on the
signature page of this Subscription Agreement;
(vii) the acquisition of and subscription for the Units by the Investor as
contemplated in this Subscription Agreement complies with or is exempt from the
applicable securities legislation of the jurisdiction of residence of the
Investor;
(viii) the Investor is and will be outside the United States when receiving and
executing this Subscription Agreement and is acquiring the Units as principal
for the Investor’s own account (except for the circumstances outlined in
paragraph 5.1), for investment purposes only, and not with a view to, or for,
resale, distribution or fractionalization thereof, in whole or in part, and no
other person has a direct or indirect beneficial interest in the Units and
underlying securities; the Investor is acquiring the Units for investment only
and not with a view to resale or distribution and, in particular, it has no
intention to distribute either directly or indirectly any of the Units or
underlying securities in the United States or to U.S. Persons; the Investor is
not an underwriter of, or dealer in, the Units of the Company, nor is the
Investor participating, pursuant to a contractual agreement or otherwise, in the
distribution of the Units or underlying securities; the Investor:

(a) is able to fend for itself in connection with the Unit Offering; and

(b) has such knowledge and experience in business matters as to be capable of
evaluating the merits and risks of its prospective investment in the Company's
Units offered hereby; and (iii) has the ability to bear the economic risks of
its prospective investment and can afford the complete loss of such investment;
if the Investor is acquiring the Units as a fiduciary or agent for one or more
investor accounts, the Investor has sole investment discretion with respect to
each such account and it has full power to make the foregoing acknowledgements,
representations and agreements on behalf of such account, and the investor
accounts, if any, for which the Investor acts as a fiduciary or agent satisfy
the definition of an "Accredited Investor", as the term is defined in Rule 501
of Regulation D under the Act; the Investor acknowledges that the Investor has
not acquired the Units as a result of, and will not itself engage in, any
"directed selling efforts" (as defined in Regulation S under the Act) in the
United States in respect of any of the Units or underlying securities which
would include any activities undertaken for the purpose of, or that could
reasonably be expected to have the effect of, conditioning the market in the
United States for the resale of any of the Units or underlying securities;
provided, however, that the Investor may sell or otherwise dispose of any of the
Units or underlying securities pursuant to an effective registration statement
under the Act and any applicable state securities laws or under an exemption
from such registration requirements and as otherwise provided herein; the
Investor acknowledges that he/she/it and has not received nor is Investor aware
of any advertisement of any of the Units; no person has made to the Investor any
written or oral representations that any person will resell or repurchase any of
the Units or underlying securities; any person will refund the purchase price of
any of the Units; and

(c) that any of the Units or underlying securities will be listed and posted for
trading on any stock exchange or automated dealer quotation system or that
application has been made to list and post any of the Units or underlying
securities of the Company on any stock exchange or automated dealer quotation
system;

(ix) the Investor:

(a) is knowledgeable of, or has been independently advised as to, the applicable
securities laws in the jurisdiction in which the Investor is resident (the
"International Jurisdiction") which would apply to the acquisition of the Units;

(b) is subscribing for the purchase of the Units pursuant to exemptions from
prospectus or equivalent requirements under applicable securities laws or, if
such is not applicable, the Investor is permitted to purchase the Units under
the applicable securities laws of the securities regulators in the International
Jurisdiction without the need to rely on any exemptions; acknowledges that the
applicable securities laws of the authorities in the International Jurisdiction
do not require the Company to make any filings or seek any approvals of any kind
whatsoever from any securities regulator of any kind whatsoever in the
International Jurisdiction in connection with the issue and sale or resale of
any of the Units or ; and

(d) represents and warrants that the acquisition of the Units by the Investor
does not trigger any obligation to prepare and file a prospectus or similar
document, or any other report with respect to such purchase in the International
Jurisdiction or any continuous disclosure reporting obligation of the Company in
the International Jurisdiction.
5.2 The Investor will, if requested by the Company, deliver to the Company an
opinion of local counsel from the International Jurisdiction which will confirm
the matters referred to in subparagraphs (ii), (iii) and (iv) of Section 5.1
above to the satisfaction of the Company, acting reasonably.

6. Acknowledgement and Waiver

The Investor has acknowledged that the decision to subscribe for and purchase
the Units was solely made on the basis of publicly available information
contained in the Public Record. The Investor hereby waives, to the fullest
extent permitted by law, any rights of withdrawal, rescission or compensation
for damages to which the Investor might be entitled in connection with the
distribution of any of the Units or underlying securities.

7. Restrictive Legend on Subject Securities

7.1 The Investor hereby acknowledges that that upon the issuance thereof, and
until such time as the same is no longer required under the applicable
securities laws and regulations, the Units and underlying securities will bear a
legend in substantially the following form:

THE SECURITIES REPRESENTED BY THE UNITS, THE SHARESAND ANY SHARES OF COMMON
STOCK ISSUABLE UPON OF THE CLASS G & CLASS H HAVE BEEN OFFERED IN AN OFFSHORE
TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN) PURSUANT TO
REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
"ACT").
NONE OF THE SECURITIES REPRESENTED THE UNITS OR ANYOF THE UNDERLYING SECURITIES
HAVE BEEN REGISTERED UNDER THE ACT, OR ANY U.S. STATE SECURITIES LAWS, AND,
UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF
REGULATION S UNDER THE ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN EACH CASE ONLY
IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING
TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE
WITH THE ACT. "UNITED STATES" AND "U.S. PERSON" ARE AS DEFINED BY REGULATION S
UNDER THE ACT.

7.2 The Investor hereby acknowledges and agrees to the Company making a notation
on its records in order to implement the restrictions on transfer set forth and
described in this Subscription Agreement.

8. Costs

The Investor acknowledges and agrees that all costs and expenses incurred by the
Investor (including any fees and disbursements of any counsel or other
professional retained by the Investor) relating to the purchase of the Units
will be borne by the Investor.

9. Governing Law

This Subscription Agreement is governed by the laws of the State of Delaware.
The Investor, in his/her/its personal or corporate capacity and, if applicable,
on behalf of each beneficial purchaser for whom it is acting, irrevocably agrees
to the jurisdiction of the courts of the State of Delaware.

10. Survival

This Subscription Agreement, including without limitation the representations,
warranties and covenants contained herein, will survive and continue in full
force and effect and be binding upon the parties hereto notwithstanding the
completion of the purchase of the Units by the Investor pursuant hereto.

11. Assignment

This Subscription Agreement is transferable or assignable only with the prior
written consent of the Company, which consent will not be unreasonably denied.

12. Severability

The invalidity or unenforceability of any particular provision of this
Subscription Agreement will not affect or limit the validity or enforceability
of the remaining provisions of this Subscription Agreement.

13. Entire Agreement

Except as expressly provided in this Subscription Agreement and in the
agreements, instruments and other documents contemplated or provided for herein,
this Subscription Agreement contains the entire agreement between the parties
with respect to the sale of the Units and underlying securities and there are no
other terms, conditions, representations or warranties, whether expressed,
implied, oral or written, by statute or common law, by the Company or by anyone
else.

14. Notices

All notices here under will be in writing and will be deemed to have been duly
given if mailed or transmitted by any standard form of telecommunication.
Notices to the Investor will be directed to the address on the Investor's
signature page and notices to the Company will be directed to it at OWC
pharmaceutical research Corp. . at the address first set forth above unless
another address will be provided to the Investor by the Company in writing.

15. Counterparts and Electronic Means

This Subscription Agreement may be executed in any number of counterparts, each
of which, when so executed and delivered, will constitute an original and all of
which together will constitute one instrument. Delivery of an executed copy of
this Subscription Agreement by electronic facsimile transmission or other means
of electronic communication capable of producing a printed copy will be deemed
to be execution and delivery of this Subscription Agreement as of the date
hereinafter set forth.

16. Delivery Instructions

16.1 The Investor hereby directs the Company to deliver the Shares and Class G &
Class H Warrants to: Investor:

Michepro Holding Ltd by Mr. Uri Heler as trustee
Address: 7 Florini Street, Greg Tower, 2nd Floor 1065, Nicosia, Cyprus

16.2 The Investor hereby directs the Company to cause the Shares and Class G &
Class H Warrant to be registered on the books of the Company as follows:

Michepro Holding Ltd, by Mr. Uri Heler as trustee
7 Florini Street, Greg Tower, 2nd Floor, Nicosia, Cyprus

IN WITNESS WHEREOF the Investor has duly executed this Subscription Agreement as
of the date of acceptance by the Company.

Michepro Holding Ltd

(Name of Investor – Please type or print)
/s/: Uri Heler, Trustee
 
(Signature and, if applicable, Title)
7 Florini Street, Greg Tower, 2nd Floor
 
(Address of Investor)
Nicosia
 
(City, State or Province, Postal Code of Investor)
Cyprus

(Country of Investor)

A C C E P T A N C E

The above-mentioned Subscription Agreement in respect of the Units is hereby
accepted by OWC Pharmaceutical Research Corp.

DATED this 3rd day of November, 2016.

OWC Pharmaceutical Research Corp.
 
/s/: Mordechai Bignitz
  Name: Mordechai Bignitz
Title: CEO